Response To Letter To Regarding Article, "Effects Of Novel Aldosterone Synthase Inhibitor For Treatment Of Primary Hypertension: Results Of A Randomized, Double-Blind, Placebo- And Active-Controlled Phase 2 Trial"

We thank Drs Keidar and Gamliel-Lazarovich for their very thoughtful comments regarding our study. We agree that it would be of interest to have been able to relate serum aldosterone levels to changes in clinic and ambulatory blood pressures after LCI699 administration.1 However, given the size and design of our study, we were not able to obtain the frequency of sampling of serum aldosterone necessary to precisely relate blood pressure changes to peak-and-trough medication effects on aldosterone. In addition, …